Evidence map›Paper›PMID 37606201›Full record

ArticleCancer biology & therapy2023

CircSETD2 inhibits YAP1 by interaction with HuR during breast cancer progression.

Lan Jing, Liu Yang, Cao Jianbo, Wan Yuqiu, Zhou Yehui

Open access · goldAbstract read
In one paragraph

Article in Cancer biology & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lan JingDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Liu YangDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Cao JianboDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Wan YuqiuDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Zhou YehuiDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.ORCID 0000-0001-6178-4230
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CircRNAs have been proven to play a pivotal role in cancer progression. The present study aims to explore the roles and related mechanisms of circSETD2 in breast cancer proliferation, migration and invasion. The expression of circSETD2 in BC was assessed by the GEO database and qRT‒PCR. The biological function and underlying molecular mechanism of circSETD2 in BC were explored using in vitro and in vivo experiments, including CCK8, transwell, RIP, western blot, and xenograft mouse models. The expression of circSETD2 was downregulated in BC tumors, in accordance with the GEO database. Overexpression of circSETD2 significantly suppressed cell growth, cell migration and invasion. Mechanistically, circSETD2 reduced the stabilization of YAP1 by competitively binding with HuR, resulting in inactivation of downstream targets such as CTGF, myc and Slug. Our work suggests that the novel signaling axis circSETD2/HuR/YAP1 plays an important role in BC progression. The molecular mechanism underlying this signaling axis may provide a potential therapeutic target for BC treatment.

Indexed as

Breast NeoplasmsAnimalsBreastCell CycleCell MovementCell ProliferationDisease Models, AnimalFemaleHumansMicebreast cancerCircSETD2HuRYAP1

Identifiers

PMID37606201
PMCPMC10446782
OpenAlexW4386046558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.